SerpinA1a Activators consist of a diverse array of chemical compounds that enhance the functionality of SerpinA1a through various biochemical mechanisms. Heparin, a well-known anticoagulant, stabilizes the conformation of SerpinA1a, potentiating its inhibitory effect on serine proteases, which is crucial for modulating proteolytic events in coagulation. Similarly, Phenylmethanesulfonyl fluoride (PMSF) and Aprotinin serve to protect SerpinA1a from proteolytic degradation, thereby preserving its ability to regulate protease activity. Epsilon-aminocaproic acid and Tranexamic acid, both plasminogen activation inhibitors, enhance SerpinA1a activity by preventing its degradation and competitive inhibition, maintaining its functional integrity within the fibrinolytic system. Inhibition of serine proteases by Gabexate mesilate and Nafamostat mesilate indirectly supports SerpinA1a's activity by minimizing its consumption and ensuring its availability to inhibit target proteases effectively.
Further contributing to the enhancement of SerpinA1a are compounds that modulate protease dynamics, such as Aliskiren, which by reducing angiotensin II production, may influence the inflammatory response and thus indirectly support SerpinA1a's activity. Camostat mesilate and Sivelestat, by inhibiting serine proteases such as TMPRSS2 and neutrophil elastase, respectively, reduce the proteolytic burden on SerpinA1a, which indirectly enhances its protease inhibitory capacity. Anistreplase indirectly augments SerpinA1a activity by altering the fibrinolytic pathway, potentially leading to a relative increase in SerpinA1a-mediated regulation. Lastly, Danaparoid supports SerpinA1a function by providing anticoagulant effects that may facilitate the preservation and enhancement of SerpinA1a's role in controlling proteolytic processes. These activators, through their targeted biochemical actions, elevate the regulatory capacity of SerpinA1a, ensuring its role in maintaining proteolytic balance is efficiently carried out without the necessity of increasing its expression levels or direct activation.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tranexamic acid | 1197-18-8 | sc-204921 sc-204921A | 5 g 10 g | $29.00 $50.00 | 10 | |
Similar to epsilon-aminocaproic acid, tranexamic acid inhibits plasminogen activation, which could indirectly enhance SerpinA1a activity by reducing proteolytic competition and degradation, maintaining the functional integrity of SerpinA1a. | ||||||
Aprotinin | 9087-70-1 | sc-3595 sc-3595A sc-3595B | 10 mg 100 mg 1 g | $112.00 $408.00 $3000.00 | 51 | |
Aprotinin is a small protein protease inhibitor that inhibits several serine proteases. Its use could potentially lessen the proteolytic burden on SerpinA1a, indirectly preserving its functional capacity to inhibit targeted proteases. | ||||||
Gabexate mesylate | 56974-61-9 | sc-215066 | 5 mg | $100.00 | ||
Gabexate mesilate inhibits various serine proteases such as thrombin and kallikrein. By inhibiting these proteases, it could reduce the consumption and inactivation of SerpinA1a, indirectly enhancing its activity. | ||||||
Nafamostat mesylate | 82956-11-4 | sc-201307 sc-201307A | 10 mg 50 mg | $82.00 $306.00 | 4 | |
Similar to gabexate, nafamostat mesilate inhibits serine proteases involved in coagulation and fibrinolysis. This inhibition could indirectly support the activity of SerpinA1a by minimizing proteolytic degradation and maintaining its inhibitory function. | ||||||
Camostat mesylate | 59721-29-8 | sc-203867 sc-203867A sc-203867B sc-203867C sc-203867D sc-203867E | 10 mg 50 mg 500 mg 1 g 10 g 100 g | $43.00 $183.00 $312.00 $624.00 $2081.00 $4474.00 | 5 | |
Camostat mesilate inhibits serine proteases like trypsin and human transmembrane protease serine 2 (TMPRSS2). By reducing serine protease activity, there could be an indirect enhancement in SerpinA1a activity due to lowered protease-mediated degradation. | ||||||
Sivelestat | 127373-66-4 | sc-203938 | 1 mg | $105.00 | 2 | |
Sivelestat selectively inhibits neutrophil elastase, which could lead to a reduced burden on SerpinA1a, indirectly enhancing its function by minimizing competition for inhibition and preserving SerpinA1a's protease inhibitory capacity. | ||||||